Table 1.
Patient characteristics.
| Donor type |
p | ||
|---|---|---|---|
| Haploidentical | Sibling-matched | ||
| n | 49 | 42 | 0.9 |
| Age (range) | 34 (17–65) | 32 (17–60) | 0.9 |
| Gender | 11 women | 14 women | 0.2 |
| 38 men | 28 men | ||
| Diagnosis | 0.8 | ||
| AML | 16 | 12 | |
| MDS | 2 | 4 | |
| ALL | 15 | 16 | |
| HD | 6 | 4 | |
| NHL | 7 | 2 | |
| SAA | 2 | 3 | |
| PNH | 1 | 1 | |
| Disease status at ALOTH | 0.9 | ||
| CR1 | 23 | 19 | |
| >CR2 | 21 | 19 | |
| SD | 5 | 4 | |
| Conditioning | 0.7 | ||
| Myeloablative | 22 | 26 | |
| Reduced intensity | 27 | 28 | |
| Time from diagnosis to ALOTH (range) | 9 (2–18) | 11 (1–24) | 0.9 |
| CD34/kg infused (range) | 5.93 (4–12) | 5.89 (3.5–12) | 0.9 |
AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; ALL: acute lymphoblastic leukemia; HD: Hodgkin's disease; NHL: non-Hodgkin lymphoma; SAA: severe aplastic anemia; PNH: paroxysmal nocturnal hemoglobinuria. CR1: first complete remission; CR2: second complete remission; SD: stable disease.